+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Ophthalmic Drugs Market 2019-2027

  • ID: 4791031
  • Report
  • Region: Global
  • 162 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan, Inc.
  • Bayer
  • Eyegate Pharmaceuticals
  • Glaxosmithkline
  • Merck & Co.
  • MORE
Market Outlook

The global ophthalmic drug market is expected to progress at a CAGR of 4.47% in terms of revenue during the forecast period 2019-2027.

Ophthalmic drugs are widely used to treat various eye-related conditions such as glaucoma, cataract, keratitis and others. These drugs can be administered in the form of ointments, creams or liquid drops. The development of advanced drug delivery techniques for ophthalmic purpose has encouraged manufacturers to further aim for developing novel approaches for treating ophthalmic disorders.

The rising aging population, large pool of patients with eye diseases, changing socio-economics & geographical trends and a large focus on combination therapies of drugs are the key drivers in the global market. In addition, frequencies of glaucoma and cataract are rising each year and are leading to the consistent growth of the ophthalmic drugs market globally. Likewise, rising investments in R&D for the advancement of novel substance is expected to drive the worldwide ophthalmic drug market. However, the presence of stringent regulations for drug approval, and patent expiration are some of the key restraints that are slowing down the global ophthalmic market growth.

The ophthalmic drug market has been segmented based on prescription type, therapeutics and end-users. Based on end-users, the market is further segregated into hospitals, eye clinics ophthalmic drugs, diagnostics centers ophthalmic drugs and patient ophthalmic drugs.

Regional Outlook

Based on geography, the global ophthalmic drug market has been segmented into Latin America, North America, Asia-Pacific, Europe and the Middle East & Africa. North America represents the largest market in the global ophthalmic drug market, followed by Europe. The Middle East & Africa and Latin America ophthalmic drug markets are anticipated to grow due to the rising aging populations and eye-related disorders among the populace.

The Asia-Pacific region is expected to progress at the highest CAGR during the forecast years. The region has also been expected to emerge as a leader for drug development. The ascent in the aging populace and the presence of dominant players in the region are responsible for the growth of the market.

Competitive Outlook

The top players in the ophthalmic drug market are Merck & Co., Akorn, Santen Pharmaceutical Co., Ltd, Abbott Laboratories, SENJU Pharmaceutical Co., Ltd, Bayer, EyeMed, Johnson and Johnson, EyeGate Pharmaceuticals, Apollo Endosurgery, Novartis AG, Sun Pharmaceuticals Industries, Ltd., GlaxoSmithKline, Allergan, Inc., Valeant, Roche Holding AG, Regeneron, Pfizer, Inc. and Cipla Pharmaceuticals.

EyeMed Vision Care, LLC is a US-based company headquartered in Ohio. The company is a subpart of the Luxottica group. It offers vision wellness plans to improve the vision of its members and their dependents. EyeMed provides products for retinal imaging and diabetic eye care. In 2014, the company announced its decision to implement an updated business model that will keep it simple for eye care professionals to do business with the company and improve exam reimbursements and profit opportunities for most network providers.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan, Inc.
  • Bayer
  • Eyegate Pharmaceuticals
  • Glaxosmithkline
  • Merck & Co.
  • MORE
1. Global Ophthalmic Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Value Chain Outlook
2.3. Vendor Scorecard
2.4. Key Insights
2.5. Porter’s Five Forces Outlook
2.5.1. Bargaining Power of Buyers
2.5.2. Bargaining Power of Supplier
2.5.3. Threats of New Entrants
2.5.4. Threats of Substitutes
2.5.5. Competitive Rivalry
2.6. Market Drivers
2.6.1. Advancement in Technology
2.6.2. Growing Geriatric Populace Worldwide
2.6.3. Rising Expenditure in Healthcare
2.6.4. Rising Occurrence of Eye Syndromes
2.7. Market Restraints
2.7.1. Delay in Drug Approvals
2.7.2. Brand Patent Expirations
2.8. Market Opportunities
2.8.1. Rise in the Rates of Ophthalmic Treatment
2.8.2. Rising Opportunities in Emerging Economies

3. Ophthalmic Drugs Market Outlook – by Prescription Types
3.1. Prescription Ophthalmic Drugs
3.2. Otc (Over-The-Counter Drugs)

4. Ophthalmic Drugs Market Outlook – by Therapeutics
4.1. Diabetic Macular Edema
4.2. Eye Cancer
4.3. Diabetic Retinopathy
4.4. Retinal Vein Occlusion
4.5. Age-Related Macular Degeneration
4.6. Conjunctivitis
4.7. Dry Eye
4.8. Glaucoma
4.9. Keratitis
4.10. Geographic Atrophy
4.11. Lens Opacification and Intraocular Lens

5. Ophthalmic Drugs Market Outlook – by End-Users
5.1. Hospitals
5.2. Eye Clinics Ophthalmic Drugs
5.3. Diagnostic Centers Ophthalmic Drugs
5.4. Patient Ophthalmic Drugs

6. Ophthalmic Drugs Market – Regional Outlook
6.1. North America
6.1.1. Country Analysis
6.1.1.1. United States
6.1.1.2. Canada
6.2. Europe
6.2.1. Country Analysis
6.2.1.1. Germany
6.2.1.2. United Kingdom
6.2.1.3. Russia
6.2.1.4. France
6.2.1.5. Italy
6.2.1.6. Spain
6.3. Asia-Pacific
6.3.1. Country Analysis
6.3.1.1. China
6.3.1.2. India
6.3.1.3. South Korea
6.3.1.4. Japan
6.3.1.5. Australia & New Zealand
6.3.1.6. Asean Countries
6.4. Middle East & Africa
6.4.1. Country Analysis
6.4.1.1. Saudi Arabia
6.4.1.2. Turkey
6.4.1.3. United Arab Emirates
6.4.1.4. South Africa
6.4.1.5. Rest of Middle East & Africa
6.5. Latin America
6.5.1. Country Analysis
6.5.1.1. Mexico
6.5.1.2. Brazil
6.5.1.3. Rest of Latin America

7. Competitive Landscape
7.1. Abbott Laboratories
7.2. Johnson and Johnson
7.3. Allergan, Inc.
7.4. Bayer
7.5. Regeneron
7.6. Akorn
7.7. Valeant
7.8. Eyemed
7.9. Senju Pharmaceutical Co., Ltd
7.10. Merck & Co.
7.11. Pfizer, Inc.
7.12. Novartis Ag
7.13. Glaxosmithkline
7.14. Eyegate Pharmaceuticals
7.15. Roche Holding Ag
7.16. Apollo Endosurgery
7.17. Santen Pharmaceutical Co., Ltd
7.18. Sun Pharmaceuticals Industries, Ltd.
7.19. Cipla Pharmaceuticals

8. Methodology and Scope
8.1. Research Scope
8.2. Sources of Data
8.3. Research Methodology

Table List
Table 1 Global Ophthalmic Drugs Market by Geography 2019-2027 ($ Million)
Table 2 Common Causes of Loss of Vision in the Elderly
Table 3 Eye Drugs Gone Off-Patent
Table 4 Global Ophthalmic Drugs Market by Prescription Type 2019-2027 ($ Million)
Table 5 Fda-Approved Drugs For Ophthalmology
Table 6 Details of Some Key Prescription Drugs
Table 7 Ophthalmic Drug Products For Over-The-Counter Human Use
Table 8 Global Ophthalmic Drugs Market by Therapeutics 2019-2027 ($ Million)
Table 9 Symptoms, Treatment and Recovery Time For Diabetic Macular Edema
Table 10 Symptoms and Treatment For Eye Cancer
Table 11 Global Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 12 Global Ophthalmic Drugs Market by Geography 2019-2027 ($ Million)
Table 13 North America Ophthalmic Drugs Market by Countries 2019-2027 ($ Million)
Table 14 United States Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 15 United States Hospital Fact Sheet, 2016
Table 16 Canada Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 17 Extrapolation of Prevalence Rate of Glaucoma by Countries
Table 18 Europe Ophthalmic Drugs Market by Countries 2019-2027 ($ Million)
Table 19 Germany Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 20 Uk Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 21 Russia Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 22 Number of Hospitals in Russia, 2015
Table 23 France Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 24 Italy Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 25 Spain Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 26 Asia-Pacific Ophthalmic Drugs Market by Countries 2019-2027 ($ Million)
Table 27 China Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 28 India Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 29 Human Resource Needs For Eye Care in India
Table 30 South Korea Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 31 Japan Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 32 Australia & New Zealand Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 33 Middle East & Africa Ophthalmic Drugs Market by Countries 2019-2027 ($ Million)
Table 34 Middle East & Africa Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 35 Latin America Ophthalmic Drugs Market by Countries 2019-2027 ($ Million)
Table 36 Latin America Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)
Table 37 Mexico Ophthalmic Drugs Market by End-Users 2019-2027 ($ Million)

Figure List
Figure 1 the Population of People Aged 65 and Over Will Double in the Next 25 Years (Million)
Figure 2 Projections For the Proportion of Geriatric (60+) Population in 2015, 2030 and 2050
Figure 3 Healthcare Expenditure Cataract Surgeries On the Rise
Figure 4 Worldwide Prevalence of Presbyopia 2015, 2020 and 2050 (Million)
Figure 5 Prevalence of Glaucoma at Global Level in 2013, 2020 and 2040 (Million)
Figure 6 Global Ophthalmic Drugs Market in Prescription Ophthalmic Drugs 2019-2027 ($ Million)
Figure 7 Global Ophthalmic Drugs Market in Otc 2019-2027 ($ Million)
Figure 8 Global Ophthalmic Drugs Market in Diabetic Macular Edema 2019-2027 ($ Million)
Figure 9 Global Ophthalmic Drugs Market in Eye Cancer 2019-2027 ($ Million)
Figure 10 Diabetic Retinopathy Prevalence in the Us 2011 and 2030 (Million)
Figure 11 Global Ophthalmic Drugs Market in Diabetic Retinopathy 2019-2027 ($ Million)
Figure 12 Global Ophthalmic Drugs Market in Retinal Vein Occlusion 2019-2027 ($ Million)
Figure 13 Global Ophthalmic Drugs Market in Age-Related Macular Degeneration 2019-2027 ($ Million)
Figure 14 Global Ophthalmic Drugs Market in Conjunctivitis 2019-2027 ($ Million)
Figure 15 Global Ophthalmic Drugs Market in Dry Eye 2019-2027 ($ Million)
Figure 16 Global Ophthalmic Drugs Market in Glaucoma Therapeutics 2019-2027 ($ Million)
Figure 17 Global Ophthalmic Drugs Market in Keratitis 2019-2027 ($ Million)
Figure 18 Global Ophthalmic Drugs Market in Geographic Atrophy 2019-2027 ($ Million)
Figure 19 Global Ophthalmic Drugs Market in Lens Opacification and Intraocular Lens 2019-2027 ($ Million)
Figure 20 Global Ophthalmic Drugs Market in Hospitals Ophthalmic Drugs 2019-2027 ($ Million)
Figure 21 Total Ophthalmic Care Hospital in United States
Figure 22 Global Ophthalmic Drugs Market in Eye Clinics Ophthalmic Drugs 2019-2027 ($ Million)
Figure 23 Eye Diseases Cases in Million Above Age of 40 in America
Figure 24 Global Ophthalmic Drugs Market in Diagnostic Centers Ophthalmic Drugs 2019-2027 ($ Million)
Figure 25 Total Visual Impairment and Blindness Cases Above Age 40 in Us (In Million)
Figure 26 Global Ophthalmic Drugs Market in Patients Ophthalmic Drugs 2019-2027 ($ Million)
Figure 27 North America Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 28 Us Population Ages 65 and Older, 1960 to 2060 (Million)
Figure 29 Us Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 30 Canada Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 31 Prevalence Rate of Retinal Disorders in Canada, 2016
Figure 32 Financial Cost Share of Retina Disorder Treatment in Canada
Figure 33 Europe Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 34 Development of the European Population Aged 65 and Over, 2010, 2025 and 2050 (Million)
Figure 35 Proportion of Optometrists and Opticians in European Countries, 2015
Figure 36 Germany Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 37 Population Ages 65 and Above (% of Total)
Figure 38 Uk Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 39 Projected Number of People Living With Sight Loss in the Uk (Million)
Figure 40 Russia Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 41 Population Aged 65 and Above in France (% of Total)
Figure 42 France Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 43 Population Aged 65 and Above in Italy (% of Total)
Figure 44 Italy Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 45 Population Aged 65 and Above in Spain (% of Total)
Figure 46 Spain Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 47 Asia-Pacific Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 48 China Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 49 India Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 50 South Korea Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 51 Number of Years For Percentage, Aged 65 and Above in Total Population to Triple
Figure 52 Population Aged 65 and Above in Japan (% of Total)
Figure 53 Japan Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 54 Population Aged 65 and Above in Australia (% of Total)
Figure 55 Australia and New Zealand Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 56 Asean Countries Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 57 Middle East & Africa Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 58 Saudi Arabia Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 59 Turkey Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 60 United Arab Emirates Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 61 South Africa Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 62 Rest of Middle East & Africa Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 63 Latin America Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 64 Aging Population in Colombia 1950-2050 (In Thousands)
Figure 65 Mexico Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 66 Percentage of People Aged 65 and Above, Mexico (1950-2050)
Figure 67 Proportion of Direct Cost of Eye Disease in Mexico, by Payer
Figure 68 Brazil Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 69 Rest of Latin America Ophthalmic Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories
  • Johnson And Johnson
  • Allergan, Inc.
  • Bayer
  • Regeneron
  • Akorn
  • Valeant
  • Eyemed
  • Senju Pharmaceutical Co., Ltd
  • Merck & Co.
  • Pfizer, Inc.
  • Novartis Ag
  • Glaxosmithkline
  • Eyegate Pharmaceuticals
  • Roche Holding Ag
  • Apollo Endosurgery
  • Santen Pharmaceutical Co., Ltd
  • Sun Pharmaceuticals Industries, Ltd.
  • Cipla Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll